Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting

JHA Clubb, TV Kudling, M Girych, L Haybout, S Pakola, F Hamdan, V Cervera-Carrascon, A Hemmes, S Grönberg-Vähä-Koskela, JM Santos, DCA Quixabeira, S Basnet, C Heiniö, V Arias, E Jirovec, S Kaptan, R Havunen, S Sorsa, A Erikat, J SchwartzM Anttila, K Aro, T Viitala, I Vattulainen, V Cerullo, A Kanerva, A Hemminki

    Research output: Contribution to journalArticleScientificpeer-review

    4 Citations (Scopus)
    Original languageEnglish
    Article number1060540
    Number of pages20
    JournalFrontiers in Immunology
    Volume14
    DOIs
    Publication statusPublished - 3 Feb 2023
    MoE publication typeA1 Journal article-refereed

    Keywords

    • PDAC
    • Syrian hamster
    • Adenovirus
    • Artificial intelligence
    • Immune checkpoint inhibitor
    • Immunotherapy
    • Molecular simulations
    • Oncolytic virus

    Cite this